Abstract
Age-related macular degeneration (AMD) is a chronic and progressive disease of the central retina that causes vision loss in people over 50 years of age. With an understanding of the role of VEGF in AMD, intravitreal anti-VEGF agents are used as the most important therapeutic tool in the management of AMD. In this review we try to discuss intravitreal ranibizumab treatment and treatment regimens in wet (neovascular) age-related macular degeneration.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
